AKUS
$2.69
Akouos
$.23
9.35%
AKUS
Earnings Whisper ®
N/A
2nd Quarter June 2022
Consensus:  ($0.79)
Revenue:  N/A
Thursday
Aug 11
7:45 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AKUS reports earnings?
Beat
Meet
Miss

Where is AKUS's stock price going from here?
Up
Flat
Down
Stock chart of AKUS
Analysts
Summary of analysts' recommendations for AKUS
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Akouos, Inc. is a precision genetic medicine company. It develops gene therapies to restore, improve and preserve physiologic hearing. The Company's product candidate includes AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos, Inc. is based in Boston, Massachusetts.